SCHEMBL2930463

SCHEMBL2930463

CCOC(=O)C(=Cc1cccc(OCc2ccccc2)c1)CC(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.59
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 2/20 0.53
PKM P14618 1/20 0.53
MAOB P27338 4/20 0.52
MAOA P21397 3/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPK1 P28482 2/20 0.49
GAA P10253 1/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
CCNB2 O95067 1/20 0.48
CDK1 P06493 1/20 0.48
CDK4 P11802 1/20 0.48
CCNB1 P14635 1/20 0.48
CCND1 P24385 1/20 0.48
CCNB3 Q8WWL7 1/20 0.48
LCK P06239 1/20 0.47
CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2930460 1.00 NR1H4 (0.59) NR1H4ALDH1A1KDM4EPKMMAOB
SCHEMBL2930457 1.00 NR1H4 (0.59) NR1H4ALDH1A1KDM4EPKMMAOB
SCHEMBL3967800 0.90 KDM4E (0.56) ALDH1A1KDM4EPKMMAOBMAOA
SCHEMBL3967797 0.90 KDM4E (0.56) ALDH1A1KDM4EPKMMAOBMAOA
SCHEMBL2933539 0.86 MEN1 (0.60) ALDH1A1KDM4EPKMMAOBMAOA
SCHEMBL3752209 0.86 MEN1 (0.60) ALDH1A1KDM4EPKMMAOBMAOA
SCHEMBL13082048 0.85 TLR4 (0.47) NR1H4ALDH1A1KDM4EMEN1KMT2A
SCHEMBL12191876 0.85 NR1H4 (0.62) NR1H4ALDH1A1KDM4EPKMMAOB
SCHEMBL5381356 0.85 NR1H4 (0.62) NR1H4ALDH1A1KDM4EPKMMAOB
SCHEMBL5485852 0.85 NR1H4 (0.62) NR1H4ALDH1A1KDM4EPKMMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298347-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY MERCK FROSST CANADA LTD (CA) 2010-11-25 US disclosed
US-20100298347-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY MERCK FROSST CANADA LTD (CA) 2010-11-25 US disclosed
EP-2229373-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY Merck Frosst Canada Ltd. (CA) 2010-09-22 EP disclosed
WO-2009070873-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY MERCK FROSST CANADA LTD. (CA) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298347-A1 SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY GPR119, GPR52, GPR35 NR1H4 64/4885ALDH1A1 2522/4885KDM4E 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.